RhumbLine Advisers
ENZ

RhumbLine Advisers’s Enzo Biochem, Inc. ENZ Stock Holding History

RhumbLine Advisers’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,155
Closed -$259K – 3123
2021
Q1 		$259K Sell
75,155
-2,420
-3% -$7.53K ﹤0.01% 2750
2020
Q4 		$195K Buy
77,575
+9,309
+14% +$20.3K ﹤0.01% 2847
2020
Q3 		$144K Sell
68,266
-9,438
-12% -$22.4K ﹤0.01% 2784
2020
Q2 		$174K Buy
77,704
+5,960
+8% +$15.3K ﹤0.01% 2819
2020
Q1 		$182K Hold
71,744
– – ﹤0.01% 2619
2019
Q4 		$189K Sell
71,744
-261
-0.4% -$780 ﹤0.01% 2765
2019
Q3 		$259K Buy
72,005
+5,715
+9% +$20.2K ﹤0.01% 2640
2019
Q2 		$223K Buy
66,290
+6,903
+12% +$24.3K ﹤0.01% 2746
2019
Q1 		$162K Sell
59,387
-1,155
-2% -$3.78K ﹤0.01% 2794
2018
Q4 		$168K Buy
60,542
+19,181
+46% +$62.8K ﹤0.01% 2786
2018
Q3 		$170K Sell
41,361
-2,850
-6% -$12.9K ﹤0.01% 2779
2018
Q2 		$229K Buy
44,211
+3,955
+10% +$24.1K ﹤0.01% 2675
2018
Q1 		$221K Sell
40,256
-1,075
-3% -$7.57K ﹤0.01% 2569
2017
Q4 		$337K Sell
41,331
-8,446
-17% -$80.7K ﹤0.01% 2406
2017
Q3 		$521K Buy
49,777
+525
+1% +$5.83K ﹤0.01% 2290
2017
Q2 		$544K Buy
49,252
+4,720
+11% +$44K ﹤0.01% 2251
2017
Q1 		$373K Buy
44,532
+1,762
+4% +$12.4K ﹤0.01% 2395
2016
Q4 		$297K Buy
42,770
+2,785
+7% +$17.8K ﹤0.01% 2500
2016
Q3 		$204K Buy
39,985
+1,000
+3% +$5.97K ﹤0.01% 2670
2016
Q2 		$233K Buy
+38,985
New +$216K ﹤0.01% 2663
2015
Q2 		– Sell
-35,115
Closed -$104K – 3094
2015
Q1 		$104K Buy
35,115
+6,800
+24% +$22.3K ﹤0.01% 2950
2014
Q4 		$126K Buy
28,315
+825
+3% +$3.93K ﹤0.01% 2932
2014
Q3 		$142K Hold
27,490
– – ﹤0.01% 2871
2014
Q2 		$144K Buy
+27,490
New +$119K ﹤0.01% 2929

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's ENZ Position: Q2 2021 in Review

RhumbLine Advisers sold out of Enzo Biochem, Inc. (ENZ) in Q2 2021, closing a stake of 75,155 shares — an estimated $259K sold.

RhumbLine Advisers first reported a position in ENZ in Q2 2014 and held it in 24 quarters. The position peaked at $544K in Q2 2017. 72 funds tracked by Wall St. Rank hold ENZ as of Q2 2021.

  • RhumbLine Advisers reported no remaining Enzo Biochem, Inc. position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 75,155 Enzo Biochem, Inc. shares in Q2 2021, an estimated $259K.
  • RhumbLine Advisers first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 24 quarters.
  • RhumbLine Advisers's Enzo Biochem, Inc. position peaked at $544K in Q2 2017.
  • 72 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.